Literature DB >> 4028022

Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation.

D Mew, V Lum, C K Wat, G H Towers, C H Sun, R J Walter, W Wright, M W Berns, J G Levy.   

Abstract

A variety of cell lines have been prepared by fusion of the murine WEH1 3B cell line with peripheral blood leukocytes from a patient with chronic granulocytic leukemia. Fusion products were selected for their ability to produce a leukemia-associated antigen (CAMAL) previously described. One such line which originally produced CAMAL subsequently lost this ability and was used as a negative control. A number of antibodies were conjugated to hematoporphyrin (HP) and tested for their ability to bind to cell lines as detected by either fluorescence or by their ability to kill cells after light activation. The antibodies used were: rabbit anti-Hu (a conventional rabbit antiserum raised to membrane preparations from normal human peripheral blood leukocytes which served as a positive control); CAMAL-1 (a monoclonal gamma 1 antibody with specificity for the CAMAL antigen); and L1210 (an irrelevant monoclonal gamma 1 antibody). HP was conjugated to the antibodies by a carbodiimide procedure. When labeled cells were examined by fluorescence microscopy, it was apparent that both the rabbit antibody and CAMAL-1:HP showed positive labeling. The ability of the antibody:HP conjugates to kill labeled cells following light activation was tested. It was shown that rabbit anti-Hu:HP and CAMAL-1:HP conjugates were capable of killing significant numbers of cells when HP concentrations were as low as 1.2 ng/10(6) cells, whereas similarly treated cells exposed to either L1210:HP or HP alone did not exhibit significant killing until concentrations reached 240 and 120 ng/10(6) cells, respectively. Further experiments in which other cell lines were tested, all at HP concentrations of 12 ng/10(6) cells, demonstrated that those lines producing CAMAL were killed, whereas negative lines were not.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4028022

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein.

Authors:  Ekaterina O Serebrovskaya; Eveline F Edelweiss; Oleg A Stremovskiy; Konstantin A Lukyanov; Dmitry M Chudakov; Sergey M Deyev
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-20       Impact factor: 11.205

2.  Phototoxic liposomes coupled to an antibody that alone cannot modulate its cell-surface antigen kill selected target cells.

Authors:  S Yemul; C Berger; M Katz; A Estabrook; R Edelson; H Bayley
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Suppressor deletion therapy: selective elimination of T suppressor cells in vivo using a hematoporphyrin conjugated monoclonal antibody permits animals to reject syngeneic tumor cells.

Authors:  J K Steele; D Liu; A T Stammers; S Whitney; J G Levy
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 4.  Photonanomedicine: a convergence of photodynamic therapy and nanotechnology.

Authors:  Girgis Obaid; Mans Broekgaarden; Anne-Laure Bulin; Huang-Chiao Huang; Jerrin Kuriakose; Joyce Liu; Tayyaba Hasan
Journal:  Nanoscale       Date:  2016-06-20       Impact factor: 7.790

5.  Selective killing of T lymphocytes by phototoxic liposomes.

Authors:  S Yemul; C Berger; A Estabrook; S Suarez; R Edelson; H Bayley
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

6.  Antibody-targeted photolysis: selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates.

Authors:  A R Oseroff; D Ohuoha; T Hasan; J C Bommer; M L Yarmush
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

7.  Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results.

Authors:  Imran Rizvi; Tri A Dinh; Weiping Yu; Yuchiao Chang; Margaret E Sherwood; Tayyaba Hasan
Journal:  Isr J Chem       Date:  2012-09       Impact factor: 3.333

Review 8.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Immunophotodiagnosis of colon carcinomas in patients injected with fluoresceinated chimeric antibodies against carcinoembryonic antigen.

Authors:  S Folli; G Wagnières; A Pèlegrin; J M Calmes; D Braichotte; F Buchegger; Y Chalandon; N Hardman; C Heusser; J C Givel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

10.  Photosensitized destruction of human bladder carcinoma cells treated with chlorin e6-conjugated microspheres.

Authors:  R Bachor; C R Shea; R Gillies; T Hasan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.